Charcot-Marie-Tooth disease type 6 is a rare genetic neuropathy that mainly affects vision and balance. People with Charcot-Marie-Tooth disease type 6 often develop progressive vision loss from optic nerve damage and may have unsteady walking, foot drop, or limb weakness. Signs usually begin in childhood to early adulthood and continue lifelong, but not everyone will have the same experience. Most people with Charcot-Marie-Tooth disease type 6 have a normal life expectancy, though daily activities can be affected. Treatment focuses on management with low-vision support, physical and occupational therapy, mobility aids, and regular follow-up with neurology and eye specialists.
Overview
Charcot-marie-tooth disease type 6Symptoms
Charcot-marie-tooth disease type 6 causes slowly progressive nerve problems: weakness in feet and lower legs, foot drop, high arches, numbness, tingling, and poor balance; hands may weaken later. Vision can decline from optic nerve damage, often affecting color vision.
Outlook and prognosis
Many living with Charcot-Marie-Tooth disease type 6 (CMT6) notice slowly progressive balance problems, leg and hand weakness, and vision changes over years. Most keep independence with tailored rehab, mobility aids, and low-vision support. Life span is typically near normal.
Causes and risk factors
Charcot-Marie-Tooth disease type 6 is caused by a genetic change affecting nerve energy and signaling, usually inherited in an autosomal dominant pattern; some cases arise spontaneously. Main risk is family history; nerve-toxic medicines, diabetes, alcohol, and smoking may worsen severity.
Genetic influences
Genetics are central in Charcot-Marie-Tooth disease type 6; it’s almost always caused by inherited variants. Most cases follow dominant inheritance, though patterns can vary. Genetic testing helps confirm diagnosis, guide family planning, and distinguish CMT6 from other neuropathies.
Diagnosis
Diagnosis relies on clinical features and family history, supported by nerve conduction studies and eye/vision testing. Genetic tests confirm the genetic diagnosis of Charcot-marie-tooth disease type 6 and identify the causative variant. Other causes of neuropathy are excluded.
Treatment and drugs
Treatment for Charcot-Marie-Tooth disease type 6 focuses on keeping you moving, steady, and independent. Care often includes physical and occupational therapy, balance training, ankle–foot orthoses, and vision support, with medications for nerve pain when needed. Regular neurology and eye follow-up helps tailor support over time.
Symptoms
In Charcot-Marie-Tooth disease type 6, the most noticeable features are weakness and thinning of muscles in the lower legs and feet, changes in feeling, and challenges with balance. Some people also develop vision changes because the optic nerve is involved. You might notice small changes at first, like tripping more on uneven ground or colors looking a little duller. When people ask about early features of Charcot-Marie-Tooth disease type 6, they’re usually talking about these subtle shifts in movement, sensation, and sight.
Muscles in the lower legs can weaken, making it harder to lift the front of the foot (foot drop). In Charcot-Marie-Tooth disease type 6, this is often an early feature. Stairs, hills, or uneven ground can feel tiring or lead to more stumbles.
Tasks like opening jars, turning keys, or buttoning clothes can take more effort. You may notice items slipping or a heavier reliance on two hands for fine tasks.
Numbness, tingling, or a “pins and needles” feeling can affect the feet and, later, the hands. It can be harder to feel small injuries or changes in temperature. Some describe burning or electric-like pain, which can come and go.
Unsteady footing, especially on gravel, grass, or in low light, is common. Many with Charcot-Marie-Tooth disease type 6 take shorter steps or watch their feet closely to stay steady. Falls or near-falls may happen more often.
How people usually first notice Charcot-marie-tooth disease type 6?
People often notice the first signs of Charcot-Marie-Tooth disease type 6 as slowly increasing clumsiness or balance problems, like tripping more often, veering when walking, or finding it harder to keep steady in low light. Because CMT6 can affect the optic nerves, early clues may also include blurry or dim vision, trouble distinguishing colors, or a gradual loss of visual sharpness, sometimes after a period of walking difficulties. Doctors typically first recognize it through a combination of a family history of CMT, a neurological exam showing distal weakness and reduced reflexes, and eye findings consistent with optic nerve involvement, which together point to how CMT6 is first noticed.
Types of Charcot-marie-tooth disease type 6
Charcot-Marie-Tooth disease type 6 (CMT6) is a rare inherited neuropathy that includes both peripheral nerve damage and vision problems from optic nerve involvement. Variants of CMT6 are defined by the specific gene changes, and these differences can influence the age when symptoms start, how quickly they progress, and which features are most prominent. People may notice different sets of symptoms depending on their situation. Understanding the main variants of CMT6 can help make sense of the types of Charcot-Marie-Tooth disease type 6 you may see in clinic notes or genetic reports.
MFN2-related CMT6
Often begins in childhood or adolescence with foot drop and weak ankles. Progressive vision loss from optic nerve damage may follow months to years later. Hearing and balance issues can occur but vary.
OPA1-related CMT6
Optic nerve problems and reduced color vision may appear early, sometimes before noticeable leg weakness. Leg and hand weakness develop gradually with high arches and frequent tripping. Some experience mild coordination or balance difficulties.
PARKIN-related CMT6
Weakness and numbness start in the feet and progress slowly. Vision changes may be milder or appear later than nerve symptoms. Tremor or stiffness can occur in a subset, especially with older onset.
C12orf65-related CMT6
Early vision loss with optic nerve involvement is common, sometimes in late childhood. Leg weakness, foot deformities, and reduced reflexes accompany vision symptoms. Some people also report fatigue and exercise intolerance.
SLC25A46-related CMT6
Onset can be in childhood with gait instability and frequent falls. Vision may decline early and progress more quickly in some families. Balance and coordination problems can be more pronounced.
RAB28-related CMT6
Peripheral neuropathy presents with numbness and burning pain in the feet. Optic nerve involvement leads to gradual vision loss over years. Symptoms often progress slowly but can vary by family.
OPA3-related CMT6
Visual decline with optic atrophy may be noticed in school years. Peripheral nerve symptoms include high arches, weak ankles, and reduced sensation. Some individuals also develop fine tremor or cramping.
What genetics can tell you about symptoms
Vision problems from optic nerve damage are linked to OPA1 gene variants, while balance issues and limb weakness often reflect MFN2 changes affecting long nerve fibers. Some people also have color vision loss or eye movement difficulties when these mitochondrial‑shaping genes are disrupted.
Causes and risk factors
Most cases of Charcot-marie-tooth disease type 6 are caused by a change in the MFN2 gene. It often runs in families, and each child of an affected parent has a 50% chance to inherit the change. Some cases start with a new change in the child, with no family history. Genes set the stage, but environment and lifestyle often decide how the story unfolds. Certain factors can worsen nerve damage or bring on early symptoms of Charcot-marie-tooth disease type 6, such as some chemotherapy drugs, heavy alcohol use, smoking, and poorly controlled diabetes.
Environmental and biological risk factors
Charcot-Marie-Tooth disease type 6 is largely determined at the moment of conception, so day-to-day exposures during childhood don’t create the condition. Risks here focus on factors that can affect the parents’ eggs or sperm before pregnancy or early in embryonic development. These risk factors do not predict the early symptoms of Charcot-Marie-Tooth disease type 6, but they relate to how likely the condition occurs in the first place. Plenty of people with similar exposures live without developing the condition.
As fathers get older, the chance of new DNA changes in sperm rises. This can slightly increase the odds of a rare, single-gene condition occurring in a child. The absolute risk remains low for most families.
Older eggs have a higher chance of DNA changes or errors during cell division. This may modestly raise the chance of a new single-gene change at conception. The increase is generally smaller than paternal age effects.
High-dose ionizing radiation to the ovaries or testes can damage DNA in reproductive cells. This could raise the chance of new genetic changes at conception. Typical medical imaging doses are far below these levels.
Some cancer therapies, such as certain chemotherapy or pelvic radiation, can harm eggs or sperm. If conception happens soon after, the chance of new genetic changes may be higher. Waiting periods are often advised to allow recovery of healthier cells.
Genetic risk factors
Charcot-marie-tooth disease type 6 (CMT6) is most often linked to changes in a single gene called MFN2, which helps mitochondria—the cell’s energy producers—work and move along long nerve fibers. These changes are usually inherited in an autosomal dominant way, though some arise for the first time in a child. They are present from birth, often long before early symptoms of Charcot-marie-tooth disease type 6 are noticed. Risk is not destiny—it varies widely between individuals.
MFN2 gene variants: Changes in the MFN2 gene are the leading genetic cause of Charcot-marie-tooth disease type 6. MFN2 helps mitochondria fuse and move inside long nerves; faulty copies strain the longest nerve fibers and the optic nerve. Finding an MFN2 change on testing usually confirms the genetic basis.
Autosomal dominant inheritance: Charcot-marie-tooth disease type 6 is most often inherited in an autosomal dominant way, where one altered copy is enough. Each child of an affected adult has a 50% (1 in 2) chance of inheriting the change. Family trees may show nerve and vision problems across several generations.
De novo variants: Some MFN2 changes arise for the first time in a child, with no prior family history. Testing parents helps confirm whether the variant was inherited or new. If parents test negative, sibling risk is usually low.
Rare recessive cases: Very rarely, CMT6-like features occur when both copies of MFN2 carry changes. These autosomal recessive cases are uncommon and may present earlier in life. A genetics professional can explain how this affects recurrence risks.
Variable expression: The same MFN2 change can lead to different ages of onset and symptom severity within a family. Carrying a genetic change doesn’t guarantee the condition will appear. This helps explain why early symptoms of Charcot-marie-tooth disease type 6 can differ from person to person.
Variant outcome clues: Some specific MFN2 changes are linked with a higher chance of optic nerve involvement or earlier neuropathy. Your genetic report may note known patterns, but they are not exact predictions. Doctors typically use this information to guide monitoring rather than forecast the course.
Mitochondrial pathway: MFN2 works in a pathway that controls mitochondrial fusion and movement within neurons. Disruption of this pathway increases vulnerability of long peripheral nerves and the optic nerve in Charcot-marie-tooth disease type 6. Science continues to uncover how these elements interact.
Lifestyle risk factors
Charcot-marie-tooth disease type 6 is a genetic neuropathy; lifestyle habits do not cause it but can shape symptoms, day-to-day function, and complications. This section focuses on how lifestyle affects Charcot-marie-tooth disease type 6 and highlights lifestyle risk factors for Charcot-marie-tooth disease type 6. Choices around activity, footwear, nutrition, and substance use can influence balance, pain, wound risk, and fatigue. Aligning habits with nerve and muscle needs may help preserve function and safety.
Long periods of sitting lead to muscle deconditioning and worse balance in CMT6. Regular low‑impact activity (like cycling, swimming, or targeted strengthening) helps maintain gait and reduce falls.
Running on hard surfaces and plyometrics can strain weak ankles and increase sprains in neuropathic feet. Choosing low‑impact training protects joints and preserves mobility.
High heels, flip‑flops, or tight shoes increase instability and pressure points on numb areas. Supportive shoes with a wide toe box and good grip lower ulcer and fall risk.
Not using ankle‑foot orthoses or missing physical therapy allows foot drop and contractures to worsen. Consistent use supports safer walking and reduces energy cost of movement.
Risk prevention
Charcot-marie-tooth disease type 6 is inherited, so you can’t fully prevent it, but you can lower risks of complications and protect day-to-day function. Prevention is about lowering risk, not eliminating it completely. Spotting early symptoms of Charcot-marie-tooth disease type 6 and addressing them promptly can help preserve mobility and vision. Ongoing care focuses on fall prevention, foot protection, eye monitoring, and tailored activity to keep you steady and independent.
Learn how CMT type 6 is passed on and discuss family planning options. Some families consider carrier testing, prenatal testing, or IVF with embryo testing.
Schedule routine visits with neurology and rehabilitation teams. Early adjustments in bracing or therapy can prevent falls and joint strain in CMT type 6.
Targeted strength, flexibility, and balance exercises help maintain stability. Low‑impact aerobic activity like swimming or cycling supports endurance without overloading weak muscles.
Well‑fitted shoes and ankle‑foot orthoses improve stability and reduce trips. They also protect numb or weak feet from blisters and injuries in CMT type 6.
Transmission
Charcot-Marie-Tooth disease type 6 is not contagious; it doesn’t spread through casual contact, food, or air. It stems from changes in certain genes and is usually inherited in an autosomal dominant way—one changed copy from either parent can cause it—though rarer autosomal recessive forms, where both gene copies need to be changed, also occur. New, first-time (de novo) gene changes can appear in a child even when neither parent has signs of Charcot-Marie-Tooth disease type 6. If a parent has an autosomal dominant form, each child has a 50% chance to inherit it; with autosomal recessive forms, two carrier parents have a 25% chance in each pregnancy to have a child with the condition. A genetics professional can explain how Charcot-Marie-Tooth disease type 6 is inherited and talk through the genetic transmission of Charcot-Marie-Tooth disease type 6 in your family.
When to test your genes
Test your genes if you have progressive balance problems, vision changes from optic atrophy, or a family history of Charcot-Marie-Tooth with vision loss. Genetic testing helps confirm CMT6, estimate risks for relatives, and guide rehab, vision care, and symptom monitoring. Consider testing before family planning or if symptoms began in childhood or teens.
Diagnosis
For many, the first step comes when everyday activities start feeling harder, like tripping on uneven ground or noticing dim light is tougher on the eyes. Charcot-marie-tooth disease type 6 is usually suspected when a pattern of slowly progressive nerve weakness in the feet and hands occurs together with vision problems from optic nerve changes. Getting a diagnosis is often a turning point toward answers and support. The genetic diagnosis of Charcot-marie-tooth disease type 6 typically combines a careful exam, nerve and eye testing, and DNA testing to confirm the cause.
Doctors look for a mix of distal muscle weakness, loss of reflexes, and sensory changes along with optic nerve–related vision loss. This combination helps point toward CMT with optic involvement rather than other neuropathies.
The exam checks strength in the lower legs and hands, balance, gait, and ankle reflexes. High arches or hammertoes and a steppage gait can support the diagnosis.
An ophthalmologist evaluates color vision, visual fields, and the optic nerve appearance. Optical coherence tomography can measure thinning of the nerve fiber layer that fits CMT type 6.
Nerve conduction studies assess how fast and how strongly signals travel in the nerves. Electromyography can show patterns that fit an axonal neuropathy rather than a demyelinating one.
Stages of Charcot-marie-tooth disease type 6
Charcot-marie-tooth disease type 6 does not have defined progression stages. The condition usually changes slowly over years and can look different from one person to another, so teams monitor overall function rather than fixed stages; early symptoms of Charcot-marie-tooth disease type 6 may include ankle weakness, frequent tripping, or noticing that vision seems less sharp. Different tests may be suggested to help confirm the diagnosis and understand which nerves and vision are affected. Doctors may use a neurologic exam, nerve conduction studies, eye and vision testing, and sometimes genetic testing to guide care over time.
Outlook and prognosis
Looking at the long-term picture can be helpful. For most people with Charcot-Marie-Tooth disease type 6 (CMT6), vision changes and balance or coordination issues progress slowly over years. You might notice trouble with night vision, more frequent stumbles on uneven ground, or fatigue after walking distances that used to feel easy. Even though it can feel overwhelming, many living with CMT6 continue school, work, and family life with adjustments like vision aids, pacing strategies, and physical therapy.
Prognosis refers to how a condition tends to change or stabilize over time. CMT6 usually leads to gradual vision loss and peripheral weakness, but the pace and degree vary widely. Some people experience early symptoms of CMT6 in childhood or adolescence, while others notice changes later in adulthood. Most studies suggest life expectancy is near normal, and deaths directly due to CMT6 are uncommon. Falls and fractures, low vision–related hazards, and fatigue can affect day-to-day safety and independence, so prevention and rehabilitation matter.
With ongoing care, many people maintain mobility, communication, and social roles for decades. Regular eye care, low-vision tools, and mobility training can preserve function, and treating mood, sleep, and pain improves quality of life. Genetic testing can sometimes provide more insight into prognosis, especially when families are planning or considering clinical trials. Talk with your doctor about what your personal outlook might look like, including how to plan for support at home, work, and in the community as needs change.
Long-term effects
Charcot-Marie-Tooth disease type 6 tends to cause slowly progressive changes in nerve and vision function over years. Early symptoms of Charcot-Marie-Tooth disease type 6 often start in the feet and hands and may later involve central vision. Everyone’s path looks different, and ongoing support can help people adapt at each stage. Most people have a normal life span, though mobility and vision needs may change over time.
Weakness usually starts in the feet and ankles and can gradually move upward. Over years, this can lead to thinner calves and difficulty standing on tiptoes or heels. Hands may later develop weakness that affects grip.
Numbness and reduced ability to feel vibration or temperature often develop in the feet and, later, the hands. This can make injuries harder to notice. Some people also feel tingling or burning sensations.
Foot drop and weak ankles can cause tripping and a steppage gait. Balance may worsen on uneven ground or in the dark. Falls can become more common over time.
High arches and curled toes can form gradually. These changes may shift pressure to certain areas of the foot. Calluses and pressure spots can follow.
How is it to live with Charcot-marie-tooth disease type 6?
Living with Charcot–Marie–Tooth disease type 6 often means planning around balance and vision changes—many notice unsteady walking, slower pace on uneven ground, and fatigue from concentrating on each step, especially in low light. Daily life may involve simple adaptations like sturdy footwear, handrails, brighter lighting, and pacing activities, along with routine eye and neurologic care to track symptoms over time. For family, friends, and coworkers, patience and practical support—offering an arm on stairs, allowing extra time, and understanding fluctuations day to day—can make participation in social and work life smoother. Many find that targeted physical therapy, low-impact exercise, and assistive devices help maintain independence and confidence.
Treatment and drugs
Treatment for Charcot–Marie–Tooth disease type 6 focuses on easing symptoms, protecting mobility and balance, and preventing complications, since there’s currently no cure. Supportive care can make a real difference in how you feel day to day. Many living with Charcot–Marie–Tooth disease type 6 work with a neurologist, physical and occupational therapists, and sometimes an eye specialist to address balance problems, leg and ankle weakness, hand coordination issues, and vision changes; braces or ankle–foot orthoses, balance and strength training, and task adaptations can reduce falls and fatigue. Doctors sometimes recommend a combination of lifestyle changes and drugs, such as pain relief for nerve pain, medications for cramps, and treatment for vision-related symptoms when needed; surgery may be considered for severe foot deformities. Research is ongoing, so ask your doctor about the best starting point for you and whether clinical trials or newer rehabilitation approaches could be a fit.
Non-drug treatment
Living with Charcot-Marie-Tooth disease type 6 often means adapting for both limb weakness and changes in vision. Alongside medicines, non-drug therapies can build strength, steady walking, and make daily tasks safer. Early symptoms of Charcot-Marie-Tooth disease type 6—like frequent tripping, hand fatigue, or noticing colors look duller—respond best when support starts early. The options below are commonly used and can be tailored to what matters most in your day-to-day life.
Targeted exercises build strength, protect joints, and improve balance. A tailored plan often includes stretching tight calves and practicing safe, efficient walking.
Hand and arm techniques make dressing, typing, and cooking easier. Simple tools like jar openers, pen grips, or button hooks can reduce strain and save time.
Light ankle-foot braces can lift the toes and prevent tripping. They support a more stable step and may reduce fatigue over longer walks.
Canes, trekking poles, or rollators improve stability on uneven ground or busy sidewalks. Choosing the right height and style helps confidence and safety.
Your genes may have an impact on how drugs work for you
For Charcot–Marie–Tooth disease type 6, genes can affect how your body processes common medications—changing how quickly you absorb, break down, or respond to them. Pharmacogenetic testing and careful dose adjustments can help clinicians choose safer, more effective options for you.
Pharmacological treatments
Medicines for Charcot-Marie-Tooth disease type 6 (CMT6) focus on easing symptoms like nerve pain, muscle cramps, and day-to-day discomfort; none reverse the underlying nerve damage. Drugs that target symptoms directly are called symptomatic treatments. Pain control can also support mobility and sleep, especially when early symptoms of Charcot-Marie-Tooth disease type 6 include burning or shooting sensations in the feet. Your care team will tailor choices to your goals, other health conditions, and how you respond over time.
Gabapentin or pregabalin can calm burning, tingling, or shooting pain from nerve injury. Duloxetine, amitriptyline, or nortriptyline are alternatives that may also help with sleep and mood.
Lidocaine 5% patches or gel can numb well-defined sore areas on the feet or ankles. Capsaicin cream or an 8% patch may reduce pain signals over time but can cause temporary burning at the site.
Acetaminophen can ease general soreness without irritating the stomach. Nonsteroidal anti-inflammatory drugs like ibuprofen or naproxen may help short term but should be used cautiously if you have stomach, kidney, or heart risks.
Mexiletine, used off-label under neuromuscular specialist care, can reduce cramps for some. It requires heart rhythm checks and is not appropriate for everyone.
Genetic influences
In many families, Charcot-Marie-Tooth disease type 6 traces back to a single change in a nerve-related gene that disrupts how signals travel to the feet and hands, and sometimes the optic nerves. It is most often inherited in an autosomal dominant way—one altered copy can cause the condition—so each child of an affected parent has about a 1 in 2 (50%) chance to inherit it. A gene change can also appear for the first time in a family (a de novo variant), and severity and age of onset can differ widely, even between close relatives. DNA testing can sometimes identify these changes. Results can confirm the cause, guide care, and clarify who else in the family could benefit from evaluation; in some families, testing helps explain early symptoms of Charcot-Marie-Tooth disease type 6. Even within one family, features can vary, so discussing inheritance and reproductive options with a genetic counselor or neurologist can help you plan.
Is Charcot-marie-tooth disease type 6 genetic?
Genetics are central in Charcot-Marie-Tooth disease type 6; it’s almost always caused by inherited variants. Most cases follow dominant inheritance, though patterns can vary. Genetic testing helps confirm diagnosis, guide family planning, and distinguish CMT6 from other neuropathies.
Pharmacogenetics—how genetics influence drug effects
Treatment for Charcot-Marie-Tooth disease type 6 focuses on symptom relief, and your genes can influence which medicines help and which cause side effects. Differences in drug-processing genes such as CYP2D6 and CYP2C19 may change how well certain antidepressants used for nerve pain (like tricyclics or SNRIs), tramadol, or codeine work, and whether you’re more prone to drowsiness, nausea, or poor pain control. Variants in CYP2C9 can also affect how you handle some anti-inflammatory pain relievers, which may shift your risk of stomach, bleeding, or liver side effects at usual doses. If carbamazepine or oxcarbazepine are considered for severe neuropathic pain or cramps, HLA testing can be important—HLA-B*15:02 in many people of East or Southeast Asian ancestry and HLA-A*31:01 in broader groups increase the risk of serious skin reactions. Regardless of genetic makeup, people with this condition are typically steered away from medicines known to worsen neuropathy, such as vincristine and some platinum-based chemotherapies, and advised to avoid very high-dose vitamin B6 supplements. Alongside your medical history and current medicines, genetic testing can help tailor doses and flag risks—pharmacogenetic testing for Charcot-Marie-Tooth disease type 6 may reduce trial-and-error and support safer choices.
Interactions with other conditions
Day-to-day, vision loss on top of hand and foot weakness can make tasks like reading labels, using stairs, or driving much harder when another health problem is in the mix. Some conditions share “underlying mechanisms,” such as problems with the cell’s energy factories (mitochondria), so CMT6 can sometimes overlap in features with other nerve and eye disorders that also affect these pathways. Other causes of nerve damage—most notably diabetes and vitamin B12 deficiency—can add to numbness, burning pain, or balance issues in Charcot-marie-tooth disease type 6, and they may speed up how quickly symptoms are noticed. When diabetes is also present, tingling or numbness can be mistaken for early symptoms of Charcot-marie-tooth disease type 6, so you may need eye and nerve testing to sort out what’s driving changes. Eye conditions like cataracts or glaucoma don’t cause CMT6, but they can further limit vision when optic atrophy is already present, so regular eye care is especially important. Interactions vary widely, so it helps to coordinate care among neurology, eye care, and primary care to adjust treatments and prevent one condition from worsening the other.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of weakness in the lower legs and feet that seemed to run through generations. A grandparent with high arches and frequent tripping, a parent who tired easily on stairs, a teen who needed ankle braces—these everyday clues were often remembered long before a name was attached. Over time, these stories guided doctors to look more closely at inherited nerve conditions that begin in the limbs and sometimes affect vision.
First described in the medical literature as a form of Charcot-Marie-Tooth disease with additional eye findings, what we now call Charcot‑Marie‑Tooth disease type 6 gradually took shape as its own subtype. Early reports focused on people with the usual features of CMT—foot drop, reduced reflexes, and muscle wasting in the calves—alongside episodes of visual blurring or loss related to the optic nerve. Initially understood only through symptoms, later case series showed that these two problems could share a single genetic cause.
With each decade, better nerve testing and eye imaging helped separate CMT type 6 from other look‑alike conditions. Doctors noticed that leg and foot symptoms often started in adolescence or early adulthood, while vision changes could appear at the same time or years later. This timing varied from family to family, and not everyone developed both limb and optic nerve issues, which made careful follow‑up essential.
Advances in genetics in the late 20th and early 21st centuries confirmed that CMT type 6 is usually passed in an autosomal dominant pattern—meaning a change in one copy of the gene can be enough to cause the condition. Identifying specific gene changes allowed clinicians to connect scattered case reports, explain why some relatives were more affected than others, and rule out unrelated causes of neuropathy or vision loss. Genetic testing also clarified that CMT type 6 is uncommon compared with other CMT types, helping set realistic expectations for families seeking information.
As medical science evolved, the definition of Charcot‑Marie‑Tooth disease type 6 became more consistent: an inherited neuropathy that primarily affects the long nerves to the feet and legs, with a recognized risk of optic nerve involvement. Not every early description was complete, yet together they built the foundation of today’s knowledge. This history explains why many people first receive a general CMT diagnosis, then learn the specific subtype after genetic testing and detailed eye and nerve evaluations.
Knowing the condition’s history can make current care feel less uncertain. It highlights why clinicians ask about family members’ walking patterns and vision changes, why they may repeat eye exams over time, and why genetic counseling is offered to relatives. Each step—observation, testing, and clearer naming—has led to more accurate diagnosis and better day‑to‑day guidance for people living with CMT type 6.